Squibb Company (NYSE:BMY) today announced that, following
discussions with the U.S. Food and Drug Administration (FDA), the
company is planning a third quarter submission of a Biologics Licensing
Application (BLA) for Opdivo ® (nivolumab) for
previously treated advanced melanoma.
for Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma investment picks